Vyome Holdings Inc. has announced positive final results from a Phase 2 proof of concept study of VT-1953 topical gel in patients with malignant fungating wounds. VT-1953, described as a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints in the study. The company plans to advance VT-1953 into a pivotal Phase III clinical trial, with the goal of seeking FDA approval. Vyome stated it remains well-capitalized through 2026 and aims to position VT-1953 as a potential treatment in a market estimated to reach $1 billion. The results of the Phase 2 study have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208813165) on December 08, 2025, and is solely responsible for the information contained therein.